KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Income from Continuing Operations (2016 - 2025)

Teva Pharmaceutical Industries' Income from Continuing Operations history spans 10 years, with the latest figure at 470000000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 270.91% year-over-year to 470000000.0, compared with a TTM value of 1403000000.0 through Dec 2025, up 171.62%, and an annual FY2025 reading of 1403000000.0, up 171.58% over the prior year.
  • Income from Continuing Operations for Q4 2025 was 470000000.0 at Teva Pharmaceutical Industries, up from 432000000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 470000000.0 in Q4 2025, with the low at 1334000000.0 in Q4 2022.
  • Average Income from Continuing Operations over 5 years is 162400000.0, with a median of 43500000.0 recorded in 2021.
  • Year-over-year, Income from Continuing Operations soared 296.23% in 2021 and then plummeted 1286.59% in 2022.
  • Tracing TEVA's Income from Continuing Operations over 5 years: stood at 151000000.0 in 2021, then crashed by 783.44% to 1334000000.0 in 2022, then surged by 134.93% to 466000000.0 in 2023, then tumbled by 159.01% to 275000000.0 in 2024, then soared by 270.91% to 470000000.0 in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Income from Continuing Operations are 470000000.0 (Q4 2025), 432000000.0 (Q3 2025), and 281000000.0 (Q2 2025).